Skip to main content
For COVID-19 vaccine updates, please
review our information guide
and
sign up for Connect
. Continue your routine care with us by scheduling an
in-person appointment
or
Video Visit
.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle menu options
Our Team
Patient Testimonials
News
For Patients
Toggle menu options
Health Information Library and Patient Resources
Support Groups and Helpful Links
Frequently Asked Questions
Your First Visit
Toggle menu options
Self-Referral
Lab Work/Procedures
Referring Physicians
Toggle menu options
Refer a Patient
Research and Clinical Trials
Toggle menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 8 results
[
Author
]
Title
Type
Year
Filters:
Author
is
Niesvizky, Ruben
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
N
Niesvizky R
,
Naib T
,
Christos PJ
,
Jayabalan D
,
Furst JR
,
Jalbrzikowski J
,
Zafar F
,
Mark T
,
Lent R
,
Pearse RN
et al.
. 2007.
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
.
Br J Haematol. 138(5):640-3.
Niesvizky R
,
Martínez-Baños D
,
Jalbrzikowski J
,
Christos P
,
Furst J
,
De Sancho M
,
Mark T
,
Pearse R
,
Mazumdar M
,
Zafar F
et al.
. 2007.
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
.
Leuk Lymphoma. 48(12):2330-7.
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
Niesvizky R
,
Coleman M
,
Mark T
. 2010.
Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.
.
Oncology (Williston Park). 24(3 Suppl 2):14-21.
Niesvizky R
,
Ely S
,
Mark T
,
Aggarwal S
,
Gabrilove JL
,
Wright JJ
,
Chen-Kiang S
,
Sparano JA
. 2011.
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
.
Cancer. 117(2):336-42.
Niesvizky R
,
Flinn IW
,
Rifkin R
,
Gabrail N
,
Charu V
,
Clowney B
,
Essell J
,
Gaffar Y
,
Warr T
,
Neuwirth R
et al.
. 2015.
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
.
J Clin Oncol. 33(33):3921-9.
Niesvizky R
,
Badros AZ
,
Costa LJ
,
Ely SA
,
Singhal SB
,
Stadtmauer EA
,
Haideri NA
,
Yacoub A
,
Hess G
,
Lentzsch S
et al.
. 2015.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(12):3320-8.
Niesvizky R
. 2013.
Immunomodulatory agents changing the landscape of multiple myeloma treatment.
.
Crit Rev Oncol Hematol. 88 Suppl 1:S1-4.